RAPID SIMULTANEOUS SCREENING (LESS THAN 23 MINUTES) OF TWENTY DRUG CLASSES FROM A SINGLE WHOLE BLOOD SAMPLE ON THE BIOCHIP ANALYSER EVIDENCE MULTISTAT

Cut-off (ng/mL)

2

V. Anderson, D. Cahir, E. McKinstry, G. Norney, P. Robinson, J. Darragh, M.L. Rodríguez, R.I. McConnell, S.P. FitzGerald. Randox Toxicology Ltd., Crumlin, United Kingdom e-mail: scientific.publications@randox.com

Introduction

Drug testing has been used in a variety of disciplines e.g. emergency medicine and clinical toxicology, criminal; justice, and workplace. Biochip array technology (BAT) enables the multi-analytical screening of drugs from a single sample, which increases the screening capacity and facilitates the testing process. By applying BAT to the fully automated Evidence MultiSTAT analyser, this study aimed to develop a simple (fully automated), rapid (<23 minutes) reliable (accurate and precise) simultaneous screening of 20 drug classes, including new psychoactive substances, from a single sample of blood.

Methodology

Assay	Agreement (%)			
	Batch I	Batch 2	Batch 3	
AB-CHMINACA	100	94	95	
AB-PINACA	100	99	100	
α-ΡΥΡ	100	100	100	
Amphetamine	100	100	100	
Barbiturates	100	100	100	
Benzodiazepines	100	98	100	
Benzoylecgonine/cocaine	99	100	100	
Buprenorphine	95	100	100	
Cannabinoids	99	100	100	
ETG	100	98	99	
Fentanyl	100	100	100	
Methadone	100	100	100	
Methamphetamine	100	100	100	
Opiate	100	97	100	
Oxycodone	100	100	100	
Phencyclidine	99	100	100	
Pregabalin	100	100	100	
Tramadol	100	100	100	
Tricyclic antidepressants	100	100	100	
6-MAM	99	100	100	

Accuracy

RANDOX TOXICOLOGY

Simultaneous biochip based immunoassays were applied to the Evidence MultiSTAT, which processes a selfcontained cartridge containing all the components required for the reactions. After simple centrifugation and dilution (1:4) the blood sample is ready to be added to the biochip. The blood sample is tested against a cut-off sample, the results are qualitative.

Repeatability (assessment of sample replicates at +50% and -50% of the cut-off), accuracy (assessment of 50 negative samples and 50 positive samples) and correlation of authentic sample results (n=113) with LC-MS/MS were determined. The results were presented as percentage agreement.

Simultaneous immunoassays and cut-offs:

Assay

AB-CHMINACA

AB-PINACA

α-PVP

18.087.128RDFT, 18.022,023.150RDFT

Authentic samples (n=113): agreement (%) biochip on Evidence MultiSTAT vs confirmatory method

Amphetamine	50		
Barbiturates	50	Assay	Agreement (%)
Benzodiazepines	20	AB-CHMINACA	99.1
Benzoylecgonine/cocaine	25	AB-PINACA	97.3
Buprenorphine	2	Amphetamine	97.3
Cannabinoids	10	Barbiturates	95.6
ETG	500	Benzodiazepines	89.4
Fentanyl	I	Benzoylecgonine/cocaine	99.1
Methadone	10	Buprenorphine	92.9
Methamphetamine	50	Cannabinoids	98.2
Opiate	80	Fentanyl	98.2
Oxycodone	10	Methadone	99.1
Phencyclidine	5	Methamphetamine	98.2
Pregabalin	1000	Opiate	99.1
Tramadol	5	Oxycodone	94.7
Tricyclic antidepressants	60	Pregabalin	90.3
6-MAM	10	Tramadol	98.2
		Tricyclic antidepressants	96.5
		6-MAM	87.6
peatability		18.029.150RDFT	
		Conclusion	

± 50% cut-off					
Assay					
Assay	Batch I	Batch 2	Batch 3		
AB-CHMINACA	97.5	97.5	100		
AB-PINACA	100	97.5	100		
a-PVP	100	100	100		
Amphetamine	100	100	100		
Barbiturates	100	97.5	100		
Benzodiazepines	97.5	100	100		
Benzoylecgonine/cocaine	100	100	97.5		
Buprenorphine	100	100	100		
Cannabinoids	97.5	100	98.8		
ETG	100	97.5	100		
Fentanyl	97.5	100	100		
Methadone	100	100	100		
Methamphetamine	100	100	100		
Opiate	100	100	100		
Oxycodone	100	100	100		
Phencyclidine	97.5	97.5	100		
Pregabalin	100	100	100		
Tramadol	100	100	100		

The results show applicability of BAT on the Evidence MultiSTAT analyser to the simple, rapid (<23 minutes) and reliable simultaneous screening of 20 drug classes from a single blood sample.



18.085.128RDFT, 18.012,019.150RDFT